title: Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses.
abstract: BACKGROUND
  Few studies have examined the long-term efficacy of fluorouracil (FU) or chemical peels for the treatment of actinic keratoses (AK). Our earlier work examined the efficacy and safety of a medium-depth chemical peel compared with the standard regimen of topical FU in the treatment of widespread facial AK through 12 months.
  
  
  OBJECTIVE
  To determine long-term efficacy of both treatments by extending our observations through 32 months.
  
  
  METHODS
  Fifteen patients with severe facial actinic damage were treated on the left side with a single application of Jessner's solution and 35% trichloroacetic acid and on the right side with twice daily applications of 5% FU cream for 3 weeks. Parameters evaluated at 1, 6, 12, and 32 months included counts of visible AK, random skin biopsies from both treatment areas, development of intercurrent neoplasms, and surveys assessing sun exposure.
  
  
  RESULTS
  Eight patients were available for reevaluation at 32 months. Both treatment sides showed a reduction in mean number of AK at 12 months followed by an increase in mean AK number between 12 and 32 months. Improvements in biopsies of clinically actinically damaged skin were seen in keratinocytic atypia, hyperkeratosis, parakeratosis, and inflammation at all treatment times during the study with both treatments. Three squamous cell carcinomas developed in the patients after initial treatment; one developed on the side treated with the peel, and two developed on the side treated with fluorouracil. Surveys failed to demonstrate an association between sun exposure and clinical response.
  
  
  CONCLUSIONS
  Based on these findings, patient with widespread actinic keratoses treated with medium-depth chemical peel or with 5% FU should be reevaluated yearly or every 1.5 years for reappearance of AK and retreatment.
authors.affiliation: Department of Otolaryngology, Ohio State University Medical Center, Columbus, USA.
authors.forename: D D
authors.initials: DD
authors.lastname: Witheiler
authors.forename: N
authors.initials: N
authors.lastname: Lawrence
authors.forename: S E
authors.initials: SE
authors.lastname: Cox
authors.forename: C
authors.initials: C
authors.lastname: Cruz
authors.forename: C J
authors.initials: CJ
authors.lastname: Cockerell
authors.forename: R G
authors.initials: RG
authors.lastname: Freemen
mesh_terms: D000287:Administration, Topical; D002615:Chemexfoliation; D004338:Drug Combinations; D000431:Ethanol / Q000008:administration & dosage*; D005148:Facial Dermatoses / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D005472:Fluorouracil / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D007642:Keratosis / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D019344:Lactic Acid / Q000008:administration & dosage*; D008297:Male; D012118:Resorcinols / Q000008:administration & dosage*; D012459:Salicylates / Q000008:administration & dosage*; D013472:Sunlight / Q000009:adverse effects*; D014238:Trichloroacetic Acid / Q000008:administration & dosage*
chemical_list: D004338:Drug Combinations; C061170:Jessner's solution; D012118:Resorcinols; D012459:Salicylates; D019344:Lactic Acid; D000431:Ethanol; D014238:Trichloroacetic Acid; D005472:Fluorouracil